Home > Boards > US Listed > Biotechs > Verastem (VSTM)

Dr. Shah on Overcoming Resistance to BTK Inhibitors

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
stockguard Member Profile
 
Followed By 15
Posts 1,247
Boards Moderated 0
Alias Born 07/09/05
160x600 placeholder
Verastem Oncology Announces Dosing of First Patient in Yakult Honsha Co., Ltd.’s Japanese Bridging Study Evaluating COPIKTR... Business Wire - 10/7/2019 7:00:00 AM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - 10/4/2019 7:00:00 AM
Verastem Oncology Receives Orphan Drug Designation from FDA for COPIKTRA for the Treatment of T-Cell Lymphoma Business Wire - 10/3/2019 2:25:00 PM
Verastem Oncology Presents New Preclinical Duvelisib Data at the 5th International Conference on New Concepts in Lymphoid Mal... Business Wire - 10/3/2019 7:00:00 AM
Verastem Oncology to Present at the Cantor 2019 Global Healthcare Conference Business Wire - 9/26/2019 7:00:00 AM
Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the 18th Annual International Workshop on Chronic Lympho... Business Wire - 9/20/2019 1:00:00 PM
Verastem Oncology to Present at the 21st Annual H.C. Wainwright Global Investment Conference Business Wire - 9/3/2019 4:05:00 PM
Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the Society of Hematologic Oncology 2019 Annual Meeting Business Wire - 9/3/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/1/2019 5:09:51 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/1/2019 4:06:59 PM
Verastem Oncology Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress Business Wire - 8/1/2019 4:05:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/31/2019 7:43:39 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/29/2019 4:17:25 PM
Verastem Oncology Appoints Brian Stuglik as Chief Executive Officer Business Wire - 7/29/2019 4:05:00 PM
Verastem in Licensing Agreement with Sanofi; Shares Up Dow Jones News - 7/25/2019 5:31:00 PM
Verastem Oncology Signs an Exclusive License Agreement with Sanofi for the Development & Commercialization of COPIKTRA® (duv... Business Wire - 7/25/2019 4:05:00 PM
Verastem Oncology to Announce Second Quarter 2019 Financial Results and Corporate Update on August 1, 2019 Business Wire - 7/25/2019 7:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 7/10/2019 4:29:18 PM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - 7/3/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/25/2019 5:12:40 PM
Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data in Peripheral T-Cell Lymphoma at the 2019 International Conference on... Business Wire - 6/21/2019 7:00:00 AM
Verastem Oncology Announces Leadership Changes Business Wire - 6/20/2019 7:00:00 AM
Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting Business Wire - 6/17/2019 7:00:00 AM
Verastem Oncology to Present at the Jefferies 2019 Global Healthcare Conference Business Wire - 5/30/2019 7:00:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 5/20/2019 5:23:17 PM
stockguard   Wednesday, 04/17/19 03:50:49 PM
Re: None
Post # of 464 
Dr. Shah on Overcoming Resistance to BTK Inhibitors in MCL
Bijal D. Shah, MD
Published: Tuesday, Apr 16, 2019

Don`t let the shorts shake you out, that`s teri game!!!!

Watch this new video:https://www.onclive.com/onclive-tv/dr-shah-on-overcoming-resistance-to-btk-inhibitors-in-mcl

Bijal D. Shah, MD, associate member, Department of Malignant Hematology, Moffitt Cancer Center, discusses overcoming resistance to BTK inhibitors in mantle cell lymphoma (MCL).

Ibrutinib (Imbruvica) and acalabrutinib (Calquence) are both FDA approved for patients with relapsed/refractory MCL, but it is not standard practice to give these agents consecutively. This is due in large part to the overlapping mechanisms that drive resistance to these BTK inhibitors, says Shah. Moreover, mutations like p53 tend to create a more aggressive disease, limiting physicians’ ability to salvage with another BTK inhibitor.

Ongoing research is looking at whether an alternative method of blocking the B-cell receptor can overcome resistance to BTK inhibition. For example, an ongoing trial is looking at the combination of duvelisib (Copiktra), a PI3K gamma and delta inhibitor, and the BCL-2 inhibitor venetoclax (Venclexta). The hope is that the combination can attack the B-cell receptor from a different angle, and in doing so indicate whether the downstream mutations are as pivotal in cancer proliferation as believed to be.




Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist